×îÐÂÉ«ÇéӰƬ

Summary: This webinar explores formulation and manufacturing strategies, enriched by case studies on lipid-based drug delivery systems and softgels.

Summary: Whether you are looking for accelerated development for your novel therapy, to transform your concepts into differentiated products to grow your brand, or lifecycle management to extend market share and maximize product value, ×îÐÂÉ«ÇéӰƬ can be your...

Summary: Zydis ODT offers rapid disintegration, a good mouthfeel and pleasant taste which plays a role in improving patient engagement in their treatment programs and offers an easy-to-take alternative to conventional oral tablets to help meet the needs of specific patient populations such as pediatric, geriatric and dysphagic patients.

This white paper provides valuable insights into the successful application of enteric polymer coatings for controlled drug delivery systems. Discover how this innovative technology can transform your oral drug formulations.

Summary: Zydis® orally disintegrating tablet (ODT) technology creates a unique, freeze-dried oral solid dosage form that disperses almost instantly in the mouth, without water. With more than 35 products launched in 60+ countries, Zydis is the world’s fastest and best-in-class ODT.

Summary: Learn more about orally disintegrating tablets as a solution to various factors that impact treatment adherence rates across various diseases.

An advanced development offering that integrates formulation expertise with on-demand Phase 1 clinical manufacturing, adaptive clinical testing and regulatory support, to help achieve flexible and efficient First-in-Human studies and expedited development.

Summary: Experts provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon.

Summary: In this webinar, experts provide an overview of the needs of different patient populations and examine the common challenges leading to non-compliance.

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies.